Original language | English |
---|---|
Pages (from-to) | A7-A8 |
Journal | American Journal of Kidney Diseases |
Volume | 73 |
Issue number | 3 |
DOIs | |
Publication status | Published - Mar 1 2019 |
Funding
Funding for the USRDS Coordinating Center is provided under contract to University of Michigan Kidney Epidemiology and Cost Center ( HHSN 276201400001C ). Dr Balkrishnan receives consulting income from Merck and Company. Dr Bragg-Gresham is a consultant with the Medical Education Institute (MEI) involving quality-of-life performance measures. Dr Herman is chair of the Data Safety Monitoring Board for Merck Sharp & Dohme. Dr Kalantar-Zadeh has financial interests with the following entities: Abbott, AbbVie, Alexion, Amgen, AstraZeneca, Aveo, Chugai, DaVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Novartis, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi, Shire, Vifor, UpToDate, and ZS Pharma. Dr Kovesdy is a consultant for AstraZeneca, Bayer, and Sanofi-Aventis. Dr Morgenstern is a consultant at Arbor Research Collaborative for Health. Dr O’Hare received grant funding from NIH, CDC, VA HSR&D; she also received speaker fees and honoraria from Dialysis Clinic Inc., Fresenius Medical Care, the University of Alabama at Birmingham, the University of Pennsylvania, and the Hammersmith Hospital in London. Dr Sim has investigator-initiated research grants from Keryx Pharmaceuticals, Mallinckrodt Pharmaceuticals, and Otsuka Pharmaceuticals. The remaining authors declare that they have no relevant financial interests. Funding for the USRDS Coordinating Center is provided under contract to University of Michigan Kidney Epidemiology and Cost Center (HHSN 276201400001C).
ASJC Scopus subject areas
- Nephrology